| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-12-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-15-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-11-2025 | 12-31-2024 | 10-K | |
| 4 | 11-12-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- SEC Filing
Wedbush analyst Martin Fan maintains Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and raises the price target from $35 t...
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...
We may offer and sell from time to time, in one or more series or issuances and in an amount and on terms that we will determin...
Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 mill...
Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO) and InnoCare Pharma L...
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(1...
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...
